HomeCompareMYMD vs BTI

MYMD vs BTI: Dividend Comparison 2026

MYMD yields 110.50% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYMD wins by $5.89M in total portfolio value
10 years
MYMD
MYMD
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full MYMD calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — MYMD vs BTI

📍 MYMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYMDBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYMD + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYMD pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYMD
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, MYMD beats the other by $1,810,537.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYMD + BTI for your $10,000?

MYMD: 50%BTI: 50%
100% BTI50/50100% MYMD
Portfolio after 10yr
$2.98M
Annual income
$1,067,808.76/yr
Blended yield
35.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

MYMD
No analyst data
Altman Z
-5.6
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYMD buys
0
BTI buys
0
No recent congressional trades found for MYMD or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYMDBTI
Forward yield110.50%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$5.93M$37.7K
Annual income after 10y$2,132,830.87$2,786.64
Total dividends collected$5.35M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: MYMD vs BTI ($10,000, DRIP)

YearMYMD PortfolioMYMD Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$21,750$11,049.72$11,299$598.92+$10.5KMYMD
2$45,733$22,460.60$12,794$703.91+$32.9KMYMD
3$93,072$44,137.91$14,518$829.07+$78.6KMYMD
4$183,537$83,949.70$16,513$978.64+$167.0KMYMD
5$351,102$154,717.47$18,827$1,157.84+$332.3KMYMD
6$652,287$276,608.54$21,518$1,373.12+$630.8KMYMD
7$1,178,220$480,272.57$24,657$1,632.46+$1.15MMYMD
8$2,071,454$810,758.34$28,329$1,945.74+$2.04MMYMD
9$3,548,616$1,332,160.25$32,637$2,325.33+$3.52MMYMD
10$5,929,850$2,132,830.87$37,708$2,786.64+$5.89MMYMD

MYMD vs BTI: Complete Analysis 2026

MYMDStock

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Full MYMD Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this MYMD vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYMD vs SCHDMYMD vs JEPIMYMD vs OMYMD vs KOMYMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.